Financial information, reports, calendar and more
Shareholder’s meetings
2018
AGM June 13, 2018
Notice (Swe: Fullständig kallelse)
Power of Attorney (Swe: Fullmakt)
2017
EGM November 23, 2017
Notice (Swe: Fullständig kallelse)
Power of Attorney (Swe: Fullmakt)
Additional material (Swe: Emission, kap 13)
AGM June 29, 2017
Notice (Swe: Fullständig kallelse)
Power of Attorney (Swe: Fullmakt)
2016
AGM May 20, 2016
Notice (Swe: Fullständig kallelse)
Power of Attorney (Swe: Fullmakt)
EGM March 14, 2016
Notice (Swe: Fullständig kallelse)
Power of Attorney (Swe: Fullmakt)
2015
AGM June 23, 2015
Notice (Swe: Fullständig kallelse)
Power of Attorney (Swe: Fullmakt)
2014
AGM May 8, 2014
Notice (Swe: Fullständig kallelse)
Power of Attorney (Swe: Fullmakt)
2013
EGM August 20, 2013
Notice (Swe: Fullständig kallelse)
Power of Attorney (Swe: Fullmakt)
AGM June 28, 2013
Notice (Swe: Fullständig kallelse)
Power of Attorney (Swe: Fullmakt)
2012
AGM April 20, 2012
Notice (Swe: Fullständig kallelse)
Power of Attorney (Swe: Fullmakt)
Affibodys latest Press releases
2018-09-24
New HER2 PET Study Uses Affibody’s ABY-025 Tracer to Individualize Breast Cancer Treatment
Affibody in short
Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.
Upcoming reports Financial calendar
- Interim Report Q2 (August 23, 2018)